22,667 Companies
Access all companiesSpotfolio tracks over one million companies in technology industries.
There are 22,667 companies in the field of Biotechnology on spotfolio that produce or deliver products, that utilize or research technologies or that are otherwise engaged in topics such as Clinical, Research, Drug, Scientific, Patients, Disease, Dr, Cell .
Start-ups (3,181)
Early-stage companies (4,638)
Established companies (11,284)
The majority of these companies is located in the following countries.
United States (10,977)
United Kingdom (1,325)
China (851)
Canada (781)
Example Companies
Find companies in your areaInternational Stem Cell Corporation International Stem Cell CORP
Access
- Technologies
- Core data such as location, employees, revenues
- Similar and peer companies
- and more
Web Quotes
aseptic processing of a sterile product (USFDA Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice;
Department of Health and Ageing (Australian equivalent of the U.S. Food and Drug Administration) and the Melbourne Health Human Research Ethics Committee ...
Tolerability of ISC-hpNSC® Injected Into the Striatum and Substantia Nigra of Patients With Parkinson’s Disease International Stem Cell Corporation is currently
Corporation (OTCQB: ISCO) () (“ISCO” or “the Company”), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products
ISCO) () (“ISCO” or “the Company”), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products
Leading Trend in the Global Stem Cell Market - April Marks Parkinson’s Disease Awareness Month - Human Stem Cells vs. Plant Stem Cells - International ...
Parkinson’s disease clinical trial. The completion of the second cohort of patients who received 50 million ISC-hpNSC® cells, which represents a biologically
Leading Trend in the Global Stem Cell Market - April Marks Parkinson’s Disease Awareness Month - Human Stem Cells vs. Plant Stem Cells - International
Directors - Scientific Advisory Board - Subsidiaries - Pipeline - Clinical Trials - Manufacturing - Science - Stem Cell Bank - Scientific Publications
Directors - Scientific Advisory Board - Subsidiaries - Pipeline - Clinical Trials - Manufacturing - Science - Stem Cell Bank - Scientific Publications
Directors - Scientific Advisory Board - Subsidiaries - Pipeline - Clinical Trials - Manufacturing - Science - Stem Cell Bank - Scientific Publications
Directors - Scientific Advisory Board - Subsidiaries - Pipeline - Clinical Trials - Manufacturing - Science - Stem Cell Bank - Scientific Publications
the UC San Diego Research Ethics Program. Since 1988, he has taught multiple seminars and courses in the responsible conduct of research. Dr. Kalichman has
Cells for Therapy and Research Cells for Therapy and Research Corporate Presentation - Dec. 17 2015 Cells for Therapy and Research 2015 Corporate Presentation
Subsidiaries - Pipeline - Clinical Trials - Manufacturing - Science - Stem Cell Bank - Scientific Publications - Intellectual Property & Licensing -
Subsidiaries - Pipeline - Clinical Trials - Manufacturing - Science - Stem Cell Bank - Scientific Publications - Intellectual Property & Licensing -
National Disease Research Interchange
Access
- Technologies
- Core data such as location, employees, revenues
- Similar and peer companies
- and more
Web Quotes
them to be directly involved in the science that leads to the discovery of drug therapies and answers questions of the disease mechanism. Playing an integral
human clinical testing, and of those that do only 10-20% make it through to drug approval. A major contributing factor to this is the Industry's reliance ...
only 5 in 5,000 drugs that enter preclinical testing progress to human clinical testing, and of those that do only 10-20% make it through to drug approval ...
Manufacture of Cell-based Therapies and Medical Devices To read more about how NDRI is sourcing human tissue for commercial manufacture of cell-based therapies
and non-profit research organizations, as well as pharmaceutical and biotechnology companies, rely on NDRI for access to human biospecimens and data in ...
National Disease Research Interchange (NDRI) has supported the progress of scientific research by partnering with organ procurement organizations (OPOs), tissue
public and private foundations and organizations, pharmaceutical and biotechnology corporations. Having served thousands of scientists with hundreds of
National Disease Research Interchange - For Researchers - For Strategic Partnering - For Recovery Partners - For Donors & Patients - About Us - NDRI ...
National Disease Research Interchange - For Researchers - For Strategic Partnering - For Recovery Partners - For Donors & Patients - About Us - NDRI
diseasesDonor Testimonials Why donate? Shared hope for a life free of disease… A legacy that could touch countless others... The opportunity to make a
immunology, neuroscience, search & rescue, medical device development and clinical education/training. CORE facilitated 420 research authorized donors in
Management Team IntroductionBoard of DirectorsExecutive Management Team Scientific Advisory Council Executive Management Team Our executive management
29, 2020 NDRI Presents Empowering Research and Discovery Award to Donor Network West The National Disease Research Interchange (NDRI), a world leader
Donors & Patients - About Us - NDRI on Instagram NDRI on Twitter NDRI on Facebook NDRI on LinkedIn NDRI on YouTube - Search Become a Donor Patients and families
Researchers - For Strategic Partnering - For Recovery Partners - For Donors & Patients - About Us - NDRI on Instagram NDRI on Twitter NDRI on Facebook NDRI on
pancreatic islet cell research. 1985 - Islet Cell Transplantation Trials NDRI provides human pancreas tissues for clinical trials on islet cell transplantation
Bolder BioTechnology Bolder BioTechnology Inc.
Access
- Technologies
- Core data such as location, employees, revenues
- Similar and peer companies
- and more
Web Quotes
Announces FDA Orphan Drug Designation for BBT-059 for Acute Radiation Syndrome - Home - News - Bolder BioTechnology Announces FDA Orphan Drug Designation for
Bolder BioTechnology and… Read more Bolder BioTechnology Announces FDA Orphan Drug Designation for BBT-059 for Acute Radiation Syndrome Boulder, Colorado – ...
Suite 210 Boulder, CO 80301 303-420-4420 News - Home - News Bolder BioTechnology Announces Positive Preclinical Data for Use of BBT-032 to Inhibit Growth ...
pandemic. Based upon these… Read more Bolder BioTechnology Announces Scientific Presentations at the 2019 Radiation Research Society Annual Meeting Boulder
Suite 210 Boulder, CO 80301 303-420-4420 News - Home - News Bolder BioTechnology Receives Continued Grant Support from the National Institutes of Health
factor (GM-CSF) to reverse Alzheimer’s disease and cognitive impairment in a mouse model of Alzheimer’s Disease - Home - News - Study: The ability of ...
conducting a clinical trial with a recombinant human GM-CSF product in patients with Alzheimer’s Disease. The 9 News series also reported on Dr. Potter’s
Boulder, CO 80301 303-420-4420 Cancer / Alzheimer’s Disease / ARS - Home - Cancer / Alzheimer’s Disease / ARS White blood cells are critical for fighting
80301 303-420-4420 Bolder BioTechnology Announces Initiation of Phase 1 Clinical Trial of BBT-015 for Treating Neutropenia and Acute Radiation Syndrome
Home - News Bolder BioTechnology Announces Positive Results from Phase 1 Clinical Trial of BBT-015, a Long-Acting G-CSF Analog, in Healthy Volunteers Boulder
Announces Scientific Presentations at the 2019 Radiation Research Society Annual Meeting - Home - News - Bolder BioTechnology Announces Scientific Presentations ...
Radiation Research Society Annual Meeting - Home - News - Bolder BioTechnology Announces Scientific Presentations at the 2019 Radiation Research Society
Health System Research Symposium - Home - News - Bolder BioTechnology Announces Presentation at the 2018 Military Health System Research Symposium Boulder
technologies to selectively modify proteins so that they last longer in patients, reducing the need for frequent administration, and in many cases improving
cancer chemotherapy, and HIV drug complications, and to boost red blood cell levels prior to elective surgeries. Annual worldwide sales of recombinant
technology. BBT-015 stimulates production of neutrophils, a type of white blood cell important for fighting bacterial infections. Annual worldwide sales of G-CSF
ImStem Biotechnology ImStem Biotechnology Inc.
Access
- Technologies
- Core data such as location, employees, revenues
- Similar and peer companies
- and more
Web Quotes
for multiple sclerosis under an IND. Earlier this year, the U.S. Food and Drug Administration (FDA) cleared IMS001 to begin a Phase 1 clinical study in ...
Financial Reports - Investor Contacts AgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent Regarding Investigational MSC Candidate ...
053 to derive IMS001 as a product candidate for development in autoimmune disease, including multiple sclerosis. To date, in patients with pneumonia and ...
Hongkui Deng Joins ImStem's Scientific Advisory Board Pluripotent stem cell expert Hongkui Deng Joins ImStem’s Scientific Advisory Board Farmington, ...
with a new generation of regenerative and cellular therapies. Pioneering research by its current founder and Chief Technology Officer Dr. Xiaofang Wang and ...
Administration (FDA) cleared IMS001 to begin a Phase 1 clinical study in patients with multiple sclerosis, after a clinical hold on its Investigational New ...
ARDS from other causes IMS001 is derived from AgeX human embryonic stem cell line ESI 053 ALAMEDA, Calif. & FARMINGTON, Conn.--(BUSINESS WIRE)-- AgeX
health and life-span Imstem Biotechnology, Inc. Imstem Biotechnology, Inc. [pronounced as "I am stem (cells)"] is a biotechnology company focusing on developing ...
organs, stem cell can also regulate the immune system to treat autoimmune disease. Our key proprietary technology is a superior and high efficient method ...
Enterprise News - Industry News - Contact Splash Slider I am the stem cell to remodel health and life-span Imstem Biotechnology, Inc. Imstem Biotechnology
Cells Products - hES-MSC - BM-MSC - hES-HSC - HSC - Clinical Development - Pipeline - Clinical Trials - Investor Relations - News and Events - Financial
Cells Products - hES-MSC - BM-MSC - hES-HSC - HSC - Clinical Development - Pipeline - Clinical Trials - Investor Relations - News and Events - Financial
technologies, we will be able to provide different kinds of therapeutic and research products with unlimited supply and consistent quality in the near future
Sana Biotechnology
Access
- Technologies
- Core data such as location, employees, revenues
- Similar and peer companies
- and more
Web Quotes
several co-sponsored by the U.S. Food and Drug Administration, European Medicines Agency and Chinese Food and Drug Administration. Stacey has a BS in chemical ...
Biological Engineering (AIMBE) fellow and has co-chaired many international scientific conferences and workshops related to CMC development strategies, including
was the Multiple Myeloma program lead, responsible for progressing multiple drug candidates, including Juno’s BCMA CAR-T, through preclinical and clinical
News - Contact © 2020 Sana Biotechnology. All rights reserved. News Press Releases Press Release Sana Biotechnology Announces Acquisition of Oscine
Our Science - Our Team - Join Us - News - Contact © 2020 Sana Biotechnology. All rights reserved. Our Team Robert Nelsen, MBA Director Back to
Science New ways to tackle disease Virtually every human disease begins with cells. At Sana, we understand that each disease is unique, and finding the ...
takes exceptional people We are making the discoveries that will change patients’ lives. As a team with expertise ranging from cellular biology to machine
engineering provide the opportunity to address the underlying cause of disease and provide benefits to patients that have previously been not possible ...
engineered cells as medicines for patients, announced its launch today. Recent scientific advances make it possible to reprogram cells in the body or replace damaged
Brunetta, MD Head of Clinical & Translational Science Back to Our Team Back Paul Brunetta, MD, is Senior Vice President of Clinical and Translational Science
teams responsible for delivering product candidates from research through clinical development towards the goal of market approval. Shanna was also the program
School, and visiting scientist at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT). Most recently, Richard
School and visiting scientist at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT). Most recently, Richard
Biotechnology, Inc. (Sana), focused on engineering cells as medicines for patients, announced today the funding of all tranches of its initial financing,
Lim, MD, PhD Head of Exploratory Cell Therapy Back to Our Team Back Bing Lim, MD, PhD, is the Head of Exploratory Cell Therapy at Sana Biotechnology.
Chuck Murry, MD, PhD CSO of Cell Therapy Back to Our Team Back Chuck Murry, MD, PhD, is Senior Vice President of Cardiac Cell Therapy Research at Sana
Topics
Search by any topicOnly spotfolio allows for searching with detailed technology terms, as we provide you with all topics that technology companies talk about.
Companies addressing these topics might be of specific interest to you, as they share more specific, niche topics.
The following topics addressed by the majority of companies help you discover major players in the field.
All companies in this field address the following more general topics.
Use Cases
Register nowTechnology scouting is the basis for your innovation management, identifies new technological developments as early as possible and protects you from disruptive business models.
Collect technology leaders, providers, start ups and potential new partners in lists via simple tagging to take further steps with your team.